Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid

Internal Medicine Journal

Volumn 33, Issue 5-6, 2003, Pages 229-234

  Ray, John ^a   Gardiner, I ^b   Marriott, D ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Drug monitoring; Isoniazid; Multidrug resistance; Rifampicin; Therapy; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG METABOLISM; DRUG MONITORING; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SPUTUM ANALYSIS; TREATMENT FAILURE; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; DRUG MONITORING; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; RIFAMPIN;

EID: 0038796548     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2003.00390.x     Document Type: Article

References (34)

1. Macintyre CR, Dwyer B, Streeton JA. The epidemiology of tuberculosis in Victoria. Med J Aust 1993; 159: 672-7.
2. Bradford WZ, Martin JN, Reingold AL, Schecter GF, Hopewell PC, Small PM. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348: 928-31.
3. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh RC. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-32.
4. Nierengarten MB. Conference report. Tuberculosis in the 21st century. Still not history. 6th Annual International Union Against Tuberculosis and Lung Disease Conference. American Lung Association of Metropolitan Chicago; 2001 Mar 1-3; Chicago, Illinois.
5. Berning SE, Huitt GA, Iseman MD. Malabsorption of antituberculosis medications in a patient with AIDS. N Engl J Med 1992; 327: 1817-18.
6. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. N Engl J Med 1993; 332: 1122-3.
7. Gordon SM, Horsburg CR, Peloquin CA, Havlik JA, Metchock B, McGowan JE et al. Low serum levels of oral antimycobacterial agents in patients with disseminated mycobacterium avium complex disease. J Infect Dis 1993; 168: 1559-62.
8. Patel K.B, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995; 332: 336-7.
9. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113: 1178-83.
10. Barakat MT, Scott J, Hughes JMB, Walport M, Calam J, Friedland JS et al. Grand rounds - Hammersmith Hospital. Persistent fever in pulmonary tuberculosis. Br Med J 1996; 313: 1543-5.
11. Morehead RS. Delayed death from pulmonary tuberculosis: unsuspected subtherapeutic drug levels. South Med J 2000; 93: 507-10.
12. Stuart RL, Wilson J, Grayson ME Isoniazid toxicity in health care workers. Clin Infect Dis 1999; 28: 895-7.
13. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327-41.
14. Israili ZH, Rogers CM, El-Attar H. Pharmacokinetics of anti-tuberculosis drugs in patients. J Clin Pharmacol 1987; 27: 78-83.
15. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108-27.
16. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharacokinet 1979; 4: 401-22.
17. Choudhri SH, Hawken M, Gathua S, Minyiri GO, Watkins W, Sahai J et al. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS and diarrhea. Clin Infect Dis 1997; 25: 104-11.
18. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Tuberculosis 1997; 18: 79-87.
19. Peloquin CA. Serum concentrations of the antimycobacterial drugs. Chest 1998; 113: 1154-5.
20. Yew WW. Therapeutic drug monitoring in antituberculosis chemotherapy. Ther Drug Monit 1998; 20: 469-72.
21. Weber A, Opheim KE, Smith A, Wong K. High-pressure liquid chromatographic quantitation of rifampicin and its two metabolites in urine and serum. Rev Infect Dis 1983; 5: S433-9.
22. Le Guellec C, Gaudet ML, Lamanetre S, Breteau M. Stability of rifampicin in plasma: consequences for therapeutic drug monitoring and pharmacokinetic studies. Ther Drug Monit 1997; 19: 669-74.
23. Peloquin CA. Rifampicin stability. Ther Drug Monit 1998; 20: 450-1.
24. Hutchings A, Spragg BP, Routledge PA. Stability of isoniazid and acetylisoniazid in saliva. Ther Drug Monit 1988; 10: 234-6.
25. Ishi M, Ogata H. Determination of rifampicin and its and metabolites in human plasma by high-performance liquid chromatography. J Chromatogr 1988; 426: 412-16.
26. Lewis RC, Hatfield NZ, Narang PK. A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromatography (HPLC). Pharm Res 1991; 8: 1434-40.
27. Hutchings A. High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids. J Chromatogr 1983; 277: 385-90.
28. Robson JM, Sullivan FM. Antituberculosis drugs. Pharmacol Rev 1963; 15: 169-223.
29. Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ME The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 895-900.
30. Mitchell RS, Bell JC. Clinical implications of isoniazid blood levels in pulmonary tuberculosis. N Engl J Med 1957; 28: 1066-70.
31. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978; 117: 991-1001.
32. Peloquin CA, Namdar R, Singleton MD, Michael D, Nix DE. Pharmacokinetics of rifampicin under fasting conditions, with food, and with antacids. Chest 1999; 115: 12-18.
33. Peloquin CA, Namdar RN, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3: 703-10.
34. Hepler CD, Strand LH. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-43.